Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Devices and Drugs in Treatment of Obesity Represent a $1.2 Bln Market Growing at Double Digit RateThe global pandemic of obesity, with particular emphasis in Western economies, is driving the development, marketing and sales of diverse treatment options at an aggressive rate, forecasted in a new report from MedMarket Diligence.
"Incidence and prevalence rates for obesity are growing at startling rates while the costs of obesity and its co-morbidities (diabetes, heart disease, many others) are becoming increasingly clear," says Patrick Driscoll, President of MedMarket Diligence. "An already dynamic group of manufacturers developing and marketing drugs and devices to target obesity will see its ranks swell as clinical practice and healthcare systems continue to demand improved treatment options." The market for products in the clinical management of obesity encompasses devices and drugs that variously focus on obesity by reducing the absorption of food, reducing appetite, creating artificial fullness, restricting stomach capacity and other methods. Given the potential appeal of drug therapy to avoid the need to undergo surgery, as is the case with many device-based obesity approaches or surgical techniques (e.g., Roux en-Y), an enormous effort, and funds have been applied to drug development, resulting in a small number of approved drugs and a growing list of drugs that have either failed trials or been withdrawn from the market. However, the demand persists, so drug companies continue to press development and clinical trials that will result in market success during the forecast period. In the interim, and beyond, device alternatives will hold favor and, in some areas, grow dramatically. The MedMarket Diligence global report on obesity, "Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019", is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity (bariatrics) The clinical management of obesity is undergoing continued change as new device and drug options are being developed and introduced alongside developing surgical options. 1. Pharmaceutical Treatment of Obesity: Past, Present and Future Drugs a. Promising Drugs That Have Failed i. Phentermine/ ii. Abbott’ iii. Vivus’ iv. Arena’ b. Prescription Drugs Currently on the Market i Appetite Suppression Drugs ii. Malabsorption Drugs iii. Satiety Drugs · Amylin’ · Novo Nordisk’s Victoza Off-Label for Obesity iv. Combination Drugs c. Areas of Pharmaceutical Research i. Melanocortin Receptor System ii. Cannabinoid Receptor Antagonists iii. GLP-1 Analogs iv. Methionine Aminopeptidase 2 (MetAP2) Inhibitor v. Appetite Suppression Drugs · Lorcaserin · NeuroSearch’ · Shionogi’ vi. Malabsorption Drugs vii. Satiety Drugs viii. Combination Drugs 2. Non- Pharmaceutical Options for Treating Obesity a. Metabolic/ i. Vertical Banded Gastroplasty ii. Roux-en- iii. Sleeve Gastrectomy iv. Biliopancreatic Diversion with Duodenal Switch v. Jejuno- b. Devices to Treat Obesity i. Restrictive Devices · Adjustable Gastric Banding · Transoral Gastroplasty (TOGA) · RESTORe Suturing System™ ii. Artificial Fullness Devices iii. Malabsorption Devices · GI Dynamics’ EndoBarrier · Gastrx Sleeve-like Device · ValenTx Sleeve iv. Devices to Control Gastric Emptying · BAROnova Therapeutics’ · BaroSense’ · Endoscopic Intragastric Injection of Botulinum Toxin v. Appetite Suppressive Devices · MetaCure’ · EnteroMedics’ · Silhouette Medical’s nObese RF Ablation Device vi. Gastric Electrical Stimulation The MedMarket Diligence Report #S835 on the global market for obesity devices and drugs is described at http://www.mediligence.com/ # # # MedMarket Diligence provides data and insight to the medical products, investment and other industries on advanced medical technologies through focused medical technology market and assessment Reports and the Medtech Startups Database. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|